NEW YORK, Feb. 5, 2014 /PRNewswire/ -- Deloitte has announced today the gold-level sponsorship of the tranSMART Foundation. As a part of Deloitte's sponsorship, Brett Davis, principal, Deloitte Consulting LLP, will join the Foundation's board of directors.
An open-source knowledge-management platform, tranSMART helps life-science and health-care organizations integrate phenotypic clinical data and molecular information to develop and refine hypotheses regarding their translational research and personalized medicine goals.
"As part of Deloitte's ongoing commitment to collaboration and innovation in health care, I am pleased to join the tranSMART Foundation board of directors," said Davis, who is also general manager of Deloitte Health Informatics. "We have been fortunate to have worked with many leading life-sciences innovators in their use of the tranSMART platform and look forward to actively participating in the Foundation to accelerate the development of leading-edge solutions to solve health-care's biggest challenges."
"Recombinant by Deloitte is one of the original developers of the tranSMART platform, and I am very pleased to see their continued involvement in the community," said Keith Elliston, Ph.D., chief executive officer of the tranSMART Foundation. "The ability of the platform to advance translational biomedical research projects and its ultimate success depends upon our global, open-source community of users and developers and the leadership of our top-tier sponsors."
Deloitte is hosting the tranSMART International Developers Conference Feb. 5-7 at its offices in Newton, MA. The meeting will convene developers from multiple organizations around the world to engage in co-development sessions, share best practices and coordinate resources to achieve release roadmap goals. A developer team will focus on execution to ensure innovations such as genomic analysis and visualization tools contributed from live production sites are incorporated into an integrated tranSMART version 1.2 release.
"The realization of personalized medicine requires solutions that allow academics and industry to openly collaborate to put the massive amounts of clinical and research data we are generating to work," said Dan Housman, director, Deloitte Consulting LLP and chief technology officer of Recombinant by Deloitte. "We are proud to have been involved in the original tranSMART platform to tackle this important challenge. We remain committed to investing in tranSMART, which is rapidly becoming the common foundation for a vibrant community of data scientists in medical research to build upon."
About The tranSMART Foundation
The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools. Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, MA., with Centers of Excellence in Ann Arbor, London, Boston and Amsterdam. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.
About Deloitte's Life Sciences and Health-Care Practice
Deloitte's life sciences and health care practice brings fresh insight to clients and industry stakeholders. Deloitte offers a distinctive menu of professional services delivered in an integrated approach that addresses many segments of the health plan, health provider and life sciences industries. For more information, visit www.deloitte.com/view/en_US/us/Industries/index.htm
As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.
Copyright © 2014 Deloitte Development LLC. All rights reserved